title: Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
abstract: The treatment of acute lymphoblastic leukemia (ALL) in adults remains challenging and novel therapies are needed. The antigen, CD19, is expressed by >90% of pre-B ALLs and represents an attractive therapeutic target. The bispecific T-cell-engaging antibody, blinatumomab, targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL. In this review, we discuss in detail the mechanism of action and key pharmacologic aspects of blinatumomab. In addition, the preclinical studies, clinical studies and toxicities are summarized.
authors.affiliation: Department of Internal Medicine, The Cleveland Clinic, Desk R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
authors.forename: Naresh
authors.initials: N
authors.lastname: Bumma
authors.affiliation: Department of Hematology/Oncology, Cleveland Clinic Lerner College of Medicine, The Cleveland Clinic, Desk R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Papadantonakis
authors.affiliation: Department of Hematology/Oncology, Cleveland Clinic Lerner College of Medicine, The Cleveland Clinic, Desk R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
authors.forename: Anjali S
authors.initials: AS
authors.lastname: Advani
mesh_terms: D018033:Antibodies, Bispecific / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; C510808:blinatumomab
keywords: acute lymphoblastic leukemia; bispecific antibody; blinatumomab; minimal residual disease; relapse